Phase I/II Study of Lenalidomide in Combination With Rituximab, Ifosfamide, Etoposide, and Carboplatin (RICER)

Trial Profile

Phase I/II Study of Lenalidomide in Combination With Rituximab, Ifosfamide, Etoposide, and Carboplatin (RICER)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Feb 2014

At a glance

  • Drugs Lenalidomide (Primary) ; Carboplatin; Carmustine; Cytarabine; Etoposide; Ifosfamide; Melphalan; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Feb 2014 Planned End Date changed from 1 Oct 2014 to 1 Dec 2014 ClinicalTrials.gov record.
    • 03 Feb 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top